Primary Results of the REPRIEVE Trial Published in NEJM

The primary results of the REPRIEVE Trial have been published and show that the statin drug pitavastatin calcium lowers the risk of heart disease in people with HIV by 35%. The results of this important large, randomized trial will have a substantial impact on the health of people with HIV.  Congratulations to the study team, led by IAS-USA Core Faculty member Dr Steven Grinspoon, for bringing these important results to the HIV community. The details and results can be accessed here: https://www.nejm.org/doi/full/10.1056/NEJMoa2304146

Findings from the REPRIEVE Trial will be featured in upcoming activities from IAS-USA and CROI.

Dr Grinspoon will discuss these results on an IAS-USA webinar on October 12, 2023.